FindTrial
Sign In

oprelvekin

BIOLOGICAL2 trials

Sponsors

National Cancer Institute (NCI), Pfizer

Conditions

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaSevere Thrombocytopenia

Phase 1

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
TerminatedNCT00012298
National Cancer Institute (NCI)Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma +6
Start: 2001-04-30End: 2010-04-30Updated: 2018-08-09

Phase 2

Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia
TerminatedNCT00886743
PfizerSevere Thrombocytopenia
Start: 2009-09-30End: 2015-12-31Updated: 2017-04-19